Drug regulator recalls drugs for epilepsy and Parkinson’s

Author: Adrian O'Dowd

Patients are being advised to check certain types of prescription-only medicines for Parkinson’s (Neupro) and epilepsy (Vimpat) that they might be using, as a precautionary measure.

The Medicines and Healthcare products Regulatory Agency (MHRA) issued an alert yesterday over some batches of the medicine which are being recalled.

The medicines are believed to be legitimate but were taken out of the regulated medicines’ supply chain during distribution and later re-introduced, said the MHRA.

That meant that the correct transport and storage conditions could not be guaranteed during this period and, while unlikely, could impact upon their effectiveness.

The medicines are stable at room temperature and there is no evidence that they were tampered with, which means the risk of the medicines not being fully effective was greatly reduced or negligible so patients should continue taking their medicine, said the agency.

If patients had any of these affected products, they should continue taking their medicines and contact their GP practice to arrange a new prescription, recommended the agency. Once they had a new prescription, patients should return the affected batches to their pharmacist.

The affected medicines are in the original Italian packaging with the UK manufacturer’s, Kosei Pharma UK Ltd, MPT Pharma Ltd, Drugsrus Ltd / P.I.E. Pharma Ltd or Doncaster Pharmaceuticals Group Ltd label or have been re-packaged in the UK manufacturers box with this batch number on.

Clinicians were advised to check their stock of all listed products for the relevant products. If any relevant packs are identified, they should be quarantined and returned to the supplier.

As a precaution, other affected medicines are also being recalled at pharmacy level and these are drugs for psoriasis (Dovobet Gel), asthma (Seretide Evohaler 250mcg), asthma and chronic obstructive pulmonary disease (DuoResp Spiromax 160mcg/4.5mcg Inhaler) and COPD only (Incruse Ellipta 55mcg Inhaler and Spiriva 18mcg Inhalation Powder Capsules).

Dr Andrew Gray, deputy director of the MHRA’s inspection, enforcement and standards division, said: “Making sure the medicines people and their families take are acceptably safe and effective is the primary role of the MHRA and is our highest priority.

“When we are made aware of potential risks to the security of the supply chain, the MHRA takes action to protect the public.”